Avadel Pharmaceuticals
Prezzo: 21.64Società e modello di business
Avadel Pharmaceuticals is a healthcare company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Its core products include the sodium oxybate formulation, which targets narcolepsy, and other specialty pharmaceuticals. The company primarily generates revenue through product sales and licensing agreements.
Profilo di investimento
The investment profile of Avadel Pharmaceuticals is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income, as it does not currently offer dividends.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 0.00 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- 13.7% ↑
- Sorpresa EPS
- -162.5% peggio del previsto
- Volatilità 20g
- 0.2% stabile
Dati FMP / FinFeed aggiornati:
2026-06-13
Racc.: Mantieni
Potenziale: 56
Rischio: 70
Aggiornato: 2026-06-13 02:50
Come funziona la raccomandazione
Perché l'AI la pensa così:
Weak fundamentals and high risk limit upside potential.
Traccia in portafoglio
Grafico prezzo
Raccomandazione AI
Previsione analista
Evento calendario
Segnale positivo
Segnale negativo
Neutrale / aggiornamento
Mantieni / informativo
B My buy
S My sell
Cambiamenti di raccomandazione AI
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-05-08 15:06 | — | Mantieni | Weak fundamentals and high risk offset potential upside. |
| 2026-05-08 05:19 | Mantieni | Mantieni | Компания показывает положительную динамику роста за последние 60 и 120 дней, однако низкий EPS и отрицательный сюрприз по доходам указывают на определенные риски. |
| 2026-03-27 07:56 | Compra | Mantieni | Компания показывает рост за последние 60 и 120 дней, однако низкий EPS и высокая степень неожиданности в отчетах указывают на потенциальные риски. |
Previsioni analisti
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2025-11-20 11:38 | Wells Fargo | Target alzato | 20 → 22.5 | 23.015 |
| 2025-10-28 07:48 | UBS | Aggiorna | — → 20 | 18.56 |
| 2025-10-23 11:37 | H.C. Wainwright | Rating peggiorato | — → 20 | 18.525 |
Ancora nulla